The NICHE phase 2 trial aimed to investigate 3-year DFS in patients with dMMR colon cancer treated with neoadjuvant ipilimumab and nivolumab. The primary endpoint were to determine safety and DFS. Researchers observed 100% 3-year DFS in dMMR colon cancer with neoadjuvant ipilimumab and nivolumab, supported by negative ctDNA. Patients with MMR-deficient (dMMR) […]
HS-20093 Shows Promise in ES-SCLC: Efficacy and Safety Results
The ARTEMIS-001 phase 1 trial aimed to present updated efficacy and safety results of HS-20093 in ES-SCLC from dose-escalation and dose-expansion phases. Efficacy endpoints were ORR, DCR, DoR, PFS, and OS. HS-20093 showed encouraging antitumor activity with manageable safety in patients with previously treated ES-SCLC. The ARTEMIS-001 study is a multicenter, open-label Phase […]
SG vs Docetaxel: OS Benefit in mNSCLC After Anti-PD-(L)1
The EVOKE-01 phase 3 trial aimed to compare the efficacy and safety of SG vs. docetaxel in patients with mNSCLC post-therapy. The primary endpoint was OS. Researchers found SG improved OS vs. docetaxel in patients with mNSCLC who were non-responsive to prior anti-PD-(L)1 therapy. Patients with metastatic non-small cell lung cancer (mNSCLC) who […]
Plinabulin + Docetaxel Improves Survival in Advanced NSCLC
The DUBLIN-3 phase 3 trial aimed to evaluate the efficacy and safety of plinabulin plus docetaxel for patients with advanced EGFR wild-type NSCLC. The primary endpoint was OS. Plinabulin plus docetaxel improved outcomes and reduced severe neutropenia in patients with advanced EGFR wild-type NSCLC. Patients with advanced/metastatic non-small-cell lung cancer (NSCLC) lacking driver […]
Role of circFAM188A in EOC Autophagy Through miR-670-3P and ULK1
The study aimed to investigate how circFAM188A regulates autophagy and invasion in OC via miR-670-3p and ULK1. Researchers noticed that circFAM188A modulates autophagy in OC by sponging miR-670-3p and interacting with ULK1. CircRNAs and autophagy play significant roles in the physiological and pathological processes of ovarian cancer (OC), yet their precise mechanisms remain […]
PTFTH Nanoplatform for TNBC Therapy
The study aimed to develop a TME-responsive nanoplatform for enhanced tumor-specific mild photothermal/gene/ferroptosis synergistic therapy in TNBC. The PTFTH nanoplatform successfully achieved a synergistic anticancer effect in vitro and holds potential for clinical application in tumor therapy. Triple-negative breast cancer (TNBC) carries one of the worst prognoses among breast cancer subtypes and urgently […]
MOST RECENT
Plasma Proteomics Predict Treatment Toxicity in NSCLC
The PROPHETIC trial aimed to develop and validate plasma proteomics-based models for predicting treatment-related toxicity in patients with NSCLC. Researchers identified distinct protein signatures linked to severe irAEs, irAE-rash, and chemo-AEs, highlighting unique toxicity mechanisms. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of metastatic non-small cell lung cancer (NSCLC). However, these therapies, […]
SIRT1-FOXO3 Axis Enhances Mitophagy & Hormone Resistance in EC
The study aimed to investigate the role of SIRT1-mediated deacetylation of FOXO3 in regulating mitophagy and hormone resistance in endometrial cancer. Researchers found that SIRT1-mediated FOXO3 deacetylation is key to mitophagy and hormone resistance in EC. Endometrial cancer (EC) is a common gynecological malignancy, particularly prevalent in developed countries, with its incidence rising […]
Impact of B4GALT5 on OC Growth and Immune Response
The study aimed to investigate B4GALT5’s impact on OC progression and the immune environment. Researchers noticed that elevated B4GALT5 expression in OC correlates with poorer outcomes and significant modulation of the immune microenvironment. Ovarian cancer (OC) is the most common primary tumor of the human reproductive system. Abnormal sialylation significantly influences tumor development, […]
CRP Enhances 5-Year Survival Prediction in GC With GLIM Model
The study aimed to develop a comprehensive model to predict the individual survival of patients with GC undergoing surgical resection. The study found that adding CRP improved the survival prediction model’s sensitivity and accuracy for patients with GC. Predicting the survival of patients diagnosed with gastric cancer (GC) who have undergone radical resection […]
Advertisement
MOST RECENT
Popular With Peers
SKB264 + KL-A167 Shows Promise in NSCLC: OptiTROP-Lung01
The study aimed to assess the efficacy and safety of combining SKB264 with KL-A167 in patients with advanced NSCLC. Researchers observed that SKB264 + KL-A167 demonstrated promising efficacy and safety; further investigation is ongoing. Sacituzumab Tirumotecan (SKB264/MK-2870) is a TROP2 ADC developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase […]
Efficacy of Fulzerasib/Cetuximab in KRAS G12C NSCLC
The phase 1 & 2 trial aimed to investigate the efficacy and safety of combining fulzerasib, with cetuximab as front-line treatment for patients with NSCLC. The primary objective was to evaluate fulzerasib with cetuximab in untreated advanced NSCLC with KRAS G12C mutation. Researchers noticed promising efficacy and safety of fulzerasib + cetuximab; further […]
TN+ SPA or RIB Therapies: Safe & Tolerated
The phase I trial aimed to assess TN’s safety and efficacy combined with SPA or RIB in advanced solid tumor patients. The results demonstrated that TN combined with SPA or RIB was well-tolerated at recommended doses, with safety profiles consistent with individual agents. Omar Saavedra Santa Gadea and the team spearheaded the study […]
VenDd Elicits Durable MRD Negativity in Myeloma
The interventional phase 2 trial aimed to compare MRD in VenDd vs. DVd RRMM. The results demonstrated that VenDd was superior MRD clearance and extended PFS in t(11;14)-positive RRMM compared to DVd. Multiple myeloma shows hematologic malignancies that involve abnormal cell proliferation in the bone marrow—the combination of venetoclax (Ven), a potent BCL-2 […]
Combined Efficacy of Tucatinib and Trastuzumab for HER2-Positive MBTC
The phase II trial aimed to evaluate the combined efficacy and safety of TUC and Tras in HER2-altered solid tumor pts. The primary endpoint was cORR. Secondary endpoints include OS, DCR, DOR, PFS, and safety. The study found that combined therapy was well-tolerated and showed promising antitumor activity in pts. Biliary tract cancer […]
Amivantamab Shows Efficacy In Pts With Advanced NSCLC
The phase 1 CHRYSALIS study evaluated amivantamab (ami) for treating advanced non-small cell lung cancer with EGFR Ex20ins mutations. Patients who had experienced disease progression on platinum-based chemotherapy were enrolled in the study. The study demonstrated the effectiveness of amivantamab in treating advanced NSCLC with EGFR Ex20ins mutations across diverse patient groups and […]
PSCA-Targeted CAR T Cells Show Promise in mCRPC Patients
The phase I trial aimed to evaluate the safety and efficacy of PSCA-targeted 4-1BB-co-stimulated CAR T cell therapy in patients with mCRPC. CAR T cells were manufactured and infused into patients with disease progression after at least 1 androgen receptor-targeted therapy. The study found that PSCA-CAR T cells can potentially treat mCRPC, but […]
CheckMate 214 Study: Clinical Efficacy of NIVO+IPI in sRCC Patients
Phase 3 of CheckMate 214 trial was conducted to study the long-term efficacy and suitability of NIVO+IPI as a 1L treatment for patients with Untreated Advanced or Metastatic Renal Cell Carcinoma with Sarcomatoid features. 139 patients were randomized in an open-label trial to compare the NIVO+IPI combination with SUN monotherapy, where NIVO+IPI proved […]
ctDNA Testing in mCRPC Patients with HRR Gene Alterations
The phase 3 PROfound study included patients with mCRPC whose plasma samples were retrospectively sequenced using circulating tumor DNA (ctDNA) Next-Generation Sequencing (NGS) to test for BRCA/ATM alterations. The efficacy of Olaparib was consistent, irrespective of the method used to identify the BRCA/ATM alterations. The study demonstrated that ctDNA NGS might be used […]
Enrolling Trials
Sign up for our emails
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Newsletter
Privacy Policy
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
SELECT ONCOLOGY JOURNAL ARTICLES
Meta-analysis of Targeted Therapies in EGFR-mutated Non–Small Cell Lung Cancer: Efficacy and Safety of Osimertinib, Erlotinib, and Gefitinib as First-line Treatment
Meta-analysis of Targeted Therapies in EGFR-mutated Non–Small Cell Lung Cancer: Efficacy and Safety of Osimertinib, Erlotinib, and Gefitinib as First-line Treatment
Background: Some of the non–small cell lung cancer (NSCLC) cases enhance somatic mutations of the epidermal growth factor receptor (EGFR) gene within the tyrosine kinase inhibitor (TKI) domain. In such cases, first-line treatments are EGFR-TKIs, …
Assessing the Impact of Multidisciplinary Cancer Consultations on Cancer Quality Metrics
Assessing the Impact of Multidisciplinary Cancer Consultations on Cancer Quality Metrics
Objective: Multidisciplinary cancer consultations play a critical role in the delivery of quality cancer care by promoting treatment planning and collaborative decision-making. The objective of this study was to evaluate associations between multidisciplinary cancer consultations …
Efficacy and Safety of Abemaciclib in Combination With Endocrine Therapy for HR+/HER2− Advanced or Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
Efficacy and Safety of Abemaciclib in Combination With Endocrine Therapy for HR+/HER2− Advanced or Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
Objectives: Breast cancer, particularly the hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2−) subtype, remains a major global health concern. Abemaciclib, a CDK4/6 inhibitor, has shown promising results in treating advanced cases. …
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS >=1%: results from a multicenter, open-label, phase 2 trial
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS >=1%: results from a multicenter, open-label, phase 2 trial
Background The combination of immune-checkpoint inhibitors and antiangiogenic agents can synergistically modulate the tumor microenvironment and represents a promising treatment option. Here, we evaluated the efficacy and safety of camrelizumab plus famitinib (a receptor tyrosine kinase …